![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Jean-Michel Pawlotsky, Shiv K. Sarin, Graham R. Foster, Cheng-Yuan Peng, Jens Rasenack, Robert Flisiak, Teerha Piratvisuth, Heiner Wedemeyer, Wan-Long Chuang, Wei Zhang and Nikolai V. Naoumov
on behalf of VITAL-1 study investigators
![AASLD1.gif](../images/111512/111512-1/AASLD1.gif)
![AASLD2.gif](../images/111512/111512-1/AASLD2.gif)
![AASLD3.gif](../images/111512/111512-1/AASLD3.gif)
![AASLD4.gif](../images/111512/111512-1/AASLD4.gif)
![AASLD5.gif](../images/111512/111512-1/AASLD5.gif)
![AASLD6.gif](../images/111512/111512-1/AASLD6.gif)
![AASLD7.gif](../images/111512/111512-1/AASLD7.gif)
![AASLD8.gif](../images/111512/111512-1/AASLD8.gif)
![AASLD9.gif](../images/111512/111512-1/AASLD9.gif)
![AASLD10.gif](../images/111512/111512-1/AASLD10.gif)
![AASLD11.gif](../images/111512/111512-1/AASLD11.gif)
![AASLD12.gif](../images/111512/111512-1/AASLD12.gif)
![AASLD13.gif](../images/111512/111512-1/AASLD13.gif)
![AASLD14.gif](../images/111512/111512-1/AASLD14.gif)
![AASLD15.gif](../images/111512/111512-1/AASLD15.gif)
![AASLD16.gif](../images/111512/111512-1/AASLD16.gif)
![AASLD17.gif](../images/111512/111512-1/AASLD17.gif)
![AASLD18.gif](../images/111512/111512-1/AASLD18.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|